The stock of Nektar Therapeutics (NASDAQ:NKTR) decreased by -$0.03 on Tuesday to finish at $0.62, down -4.25 percent. The last five days have seen an average of 2,374,600 shares of common stock traded. 15 times new highs were reached in the current year, with a fall of -$1.6384. The average number of shares traded over the last 20 days was 15,141,285, while the average volume over the last 50 days totaled 8,212,851.
NKTR stock appreciated 16.01% since last month. On 08/02/23, the company’s shares reached a one-month low of $0.5061. The stock touched a high of $4.40 on 02/07/23, after rallying from a low of $0.51 in 52 weeks. The price of NKTR stock has declined by -72.50% or -$1.6384 this year, reaching a new high 15 times. Still, the stock price is down -85.87% from the 52-week high.
Top 5 AI Stocks to Buy for 2023
The artificial intelligence (AI) revolution is already here. And it's about to change everything we know about everything.
According to Grand View Research, the global AI boom could grow from about $137 billion in 2022 to more than $1.81 trillion by 2030. And investors like you always want to get in on the hottest stocks of tomorrow. Here are five of the best ways to profit from the AI boom.
Click Here to Download the FREE Report.
Sponsored
Insider Transactions
NKTR stock investors should be aware that Nektar Therapeutics (NKTR) stock had its last reported insider trading activity 14 days ago on Aug 16. On Aug 16, President & CEO ROBIN HOWARD W sold 19,998 shares at $0.78 each. This transaction resulted in the insider making $15,598. On Aug 16, Zalevsky Jonathan sold 9,703 shares at a price of US$0.78. After the transaction, the insider now owns 283,685 shares. Chief Legal Officer Wilson Mark Andrew had earlier sold 7,221 shares on Aug 16 for $0.78 a share. The transaction was completed for $5,632.
Valuation Metrics
Beta for the stock is 0.95. There are also a few other valuation ratios worth considering, including the trailing price-to-sales (P/S) ratio of 1.36, the price-to-book (PB) ratio of 0.60.
Financial Health
For the three months ended June 29, Nektar Therapeutics’s quick ratio was 8.30, while its current ratio was 8.70, indicating its ability to pay off its debt. As far as profitability goes, gross margin for the trailing twelve months is 71.20% percent. Based on annual data, it had gross profit of $70.42 million and revenue of $92.06 million.
Investors will also look at the performance of the company’s management in order to determine the potential profitability of their investment. NKTR’s return on assets (ROA) during the last 12 months has been -48.20%. There was a -103.50% return on investment (ROI) in the past year. In the meantime, the return on equity (ROE) for the last 12 months was -100.90%.
Earnings Surprise
According to Nektar Therapeutics’s quarterly financial report for the quarter that ended June 29. A lower net income was reported in the quarter under review than the previous quarter. Net income for the quarter came in at $20.5 million, while revenues fell by -5.32% to $21.59 million. It was predicted that Nektar Therapeutics’s quarterly earnings would be -$0.27, but it ended up being -$0.28, beating the consensus by 3.60%. EBITDA was -$53.45 million for the quarter. At the end of Nektar Therapeutics’s most recent quarter ended June 29, its liabilities totaled 297.32 million, while its total debt was $124.75 million. Equity owned by shareholders amounts to $190.12 million.
Technical Picture
Here’s a quick look at Nektar Therapeutics’s (NKTR) price momentum from a technical perspective. As of 29 August, the RSI 9-day stood at 37.92%, suggesting the stock is Neutral, with a 45.68% historical volatility rate.
The stochastic %K and %D were 2.90% and 5.66% respectively, while the average true range (ATR) was 0.0719. Based on the 14-day stochastic reading of 0.34%, the RSI (14) reading is 43.69%. On the 9-day MACD Oscillator, the stock is at -0.0398, and the 14-day reading is at -0.1114.
Analyst Ratings
In its most recent analyst report, Jefferies raised its rating on Nektar Therapeutics (NASDAQ: NKTR) to a Hold. Prior to this, analysts firm rated the stock as an Underperform. Analysts have assigned Nektar Therapeutics (NKTR) an Hold rating. NKTR is a stock that is recommended for selling by 1 brokerage firm, while 6 companies recommend holding. The stock is underweighted by 1 analyst. Among the analysts who rate the stock, 0 rates it overweight and 0 others recommend it as a buy.
What is NKTR’s price target for the next 12 months?
The current consensus forecast for the stock is between $0.60 and $6.00, with a median target price of $1.75. In analyzing these forecasts, the average price target given by analysts for Nektar Therapeutics (NKTR) is $2.35.
